Poster Session

P1-072 THE EFFECT AND TOLERABILITY OF MTOR INHIBITORS FOR METASTATIC RENAL CELL CARCINOMA

S. Tamada, T. Iguchi, H. Kawashima, T. Nakatani
The Department of Urology, Osaka City University Graduate School of Medicine

Introduction: While sunitinib has been established for metastatic renal cell carcinoma as the first line therapy, there is no recommended treatment as the second line. Currently, two mTOR inhibitors have been used in general, however, axitinib is recently available. Therefore we investigated the effect of two mTOR inhibitors and examined the tolerability of them.

Subjects and Methods: Fifty four patients were treated with Everolimus (Eve) (38 cases) and temsirolimus (Tem) (16 cases) from 2010 until March 2012. We summarized the entire PFS, each PFS and side effects.

Result: Second-line uses; Eve 76%, Tem 94%, third-line used; Eve 24%, Tem 6% Duration of administration (median); Eve 8 months, Tem 4.2 months Reasons for discontinuing; Eve PD53%, AE34%, Tem PD63%, AE12.5% Entire PFS (median); 7 months Each PFS (median); Eve 10.8 months, Tem 5.2 months Interstitial lung disease; Eve 37%, Tem 13%

Conclusion: The treatment of mTOR inhibitors as the second line showed acceptable results. Everolimus was likely to more effective than Temsirolimus, while adverse events in the Everolimus were more serious.